CHEST
Original ResearchPulmonary ProceduresThe Use of Indwelling Tunneled Pleural Catheters for Recurrent Pleural Effusions in Patients With Hematologic Malignancies: A Multicenter Study
Section snippets
Results
Ninety-one patients were identified from eight institutions between January 2009 and December 2013 (Table 1). No patients were excluded from subsequent analyses. The mean ± SD age within the cohort was 65.4 ± 15.4 years (range, 22-93 years). Malignancy was present in 96% (87 of 91 patients), with lymphoma being the most commonly identified malignancy (62%) followed by leukemia (21%) and multiple myeloma (13%). Four patients were classified as other (two with amyloidosis and two with
Discussion
We present, to our knowledge, the largest study to examine clinical outcomes related to the placement of IPCs for recurrent pleural effusion in patients with underlying hematologic malignancies. The mean time to IPC removal of all catheters within the cohort was 89.9 days, but in patients undergoing spontaneous pleurodesis the mean time to removal was 63.2 days. Univariate analysis was unable to identify clinical predictors of spontaneous pleurodesis within this cohort.
We identified a 7.7%
Acknowledgments
Author contributions: C. R. G. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. C. R. G. and L. Y. contributed to the data collection, data analysis, manuscript writing, and manuscript review; H. J. L. contributed to the data analysis, manuscript writing, and manuscript review; J. H. S., F. M., M. W., P. J. C., J. B., D. S., A. C. A., S. S., J. A. G., C. L. W., and D. F.-K. contributed to the data
References (18)
- et al.
Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study
Chest
(2013) - et al.
Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion
Chest
(2006) - et al.
Recent therapeutic advances in hematological malignancies: dealing with treatment-related complications
Ann Oncol.
(2008) - et al.
Pleural effusions in hematologic malignancies
Chest
(2004) - et al.
Management of pleural effusions in children with malignant lymphoma
J Pediatr Surg
(1999) - et al.
BTS guidelines for the management of malignant pleural effusions
Thorax
(2003) - et al.
Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases
J Cardiothorac Surg
(2010) - et al.
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
Thorax
(2010) - et al.
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial
JAMA
(2012)
Cited by (42)
Indwelling tunneled pleural catheter infections and host related factors
2024, Respiratory MedicineEfficacy and Safety of Indwelling Catheter for Malignant Pleural Effusions Related to Timing of Cancer Therapy: A Systematic Review
2023, Archivos de BronconeumologiaUpdate on the diagnosis and management of malignant pleural effusions
2022, Respiratory MedicineCitation Excerpt :More recent studies have confirmed this, with overall rates of any infection generally around 5% and mortality related to such infections of less than 1% [101–103]. This remains true even in those patients receiving antineoplastic therapy or who are otherwise immunocompromised [102–104]. The largest such study to date evaluated 1318 patients who had 1408 TIPC placed for MPE or paramalignant effusions.
Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications
2019, ChestCitation Excerpt :The most important complication of IPCs was empyema, diagnosed in 10 patients (16.1%). This rate is higher than that reported thus far in patients with IPCs placed following solid organ transplantation (11%) and in those with hematologic malignancies undergoing chemotherapy (5.2%-7.7%).24-26 However, this rate is almost identical to that seen in a prospective feasibility study (16.7%) assessing IPCs as a bridge-to-transplant strategy in patients with HH at a separate liver transplant referral institution.18
Optimizing the study of tunneled intrapleural catheters for malignant pleural effusions
2018, Journal of Thoracic and Cardiovascular SurgeryPleural effusion in multiple myeloma
2018, Revista Clinica Espanola
FUNDING/SUPPORT: There was no funding available for the performance of this study. The use of the REDCap database was supported by the Penn State Clinical and Translational Research Institute; a University of Pennsylvania Clinical and Translational Research Award; and a National Institutes of Health, National Center for Research Resources [Grant UL1RR033184].
originally published Online First March 19, 2015.